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In coronary arteries, plaque disruption, the major acute clinical manifestations of atherosclerosis, leads to a subsequent
cardiac event, such as acute myocardial infarction (AMI) and unstable angina pectoris (UA). Numerous reports have
shown that high expression of MMP-9 (matrix metalloproteinase-9), MMP-13 (matrix metalloproteinase-13) and EMMPRIN
(extracellular matrix metalloproteinase induce) in monocyte/macrophage results in the plaque progression and
destabilization. Curcumin exerts well-known anti-inflammatory and antioxidant effects and probably has a protective role
in the atherosclerosis. The purpose of our study was to investigate the molecular mechanisms by which curcumin affects
MMP-9, MMP13 and EMMPRIN in PMA (phorbol 12-myristate 13-acetate) induced macrophages. Human monocytic cells
(THP-1 cells) were pretreated with curcumin or compound C for 1 h, and then induced by PMA for 48 h. Total RNA and
proteins were collected for real-time PCR and Western blot analysis, respectively. In the present study, the exposure to
curcumin resulted in attenuated JNK, p38, and ERK activation and decreased expression of MMP-9, MMP-13 and EMMPRIN
in PMA induced macrophages. Moreover, we demonstrated that AMPK (AMP-activated protein kinase) and PKC (Protein
Kinase C) was activated by PMA during monocyte/macrophage differentiation. Furthermore, curcumin reversed PMA
stimulated PKC activation and suppressed the chronic activation of AMPK, which in turn reduced the expression of
MMP-9, MMP-13 and EMMPRIN. Therefore, it is suggested that curcumin by inhibiting AMPK-MAPK (mitogen activated
protein kinase) and PKC pathway may led to down-regulated EMMPRIN, MMP-9 and MMP-13 expression in PMA-induced
THP-1 cells.
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EMMPRIN, also termed CD147 or M6 antigen, is a 58-
kDa cell surface glycoprotein described first in tumor
cells. It participates in numerous physiological processes,
play a central role in tumor metastasis, cell adhesion,
angiogenesis, chemoresistance and atherosclerosis [1,2].
EMMPRIN has been reported to stimulates secretion of
MMP-9 (matrix metalloproteinase-9) in monocytes [1,3],
have strong positive correlation with MMP13 [4,5] or
several MMPs in other cells [6,7], and activates MMP-9* Correspondence: changqianwang@hotmail.com; susiehzq@126.com
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unless otherwise stated.in atherosclerotic plaque [8]. MMP-9 belongs to a family
of zinc- and calcium-dependent endopeptidases. It is a
92 kDa protein that regulates numerous cell activities,
involving in various physiological functions, such as cell-
cell contact, tissue remodeling cell migration and cellu-
lar differentiation [9]. Recent data showed that increased
EMMPRIN expression affects plaque stability [1,8], and
accelerates the transition from a stable plaque to an un-
stable plaque in atherogenic cells, such as monocytes/
macrophages and coronary smooth muscle cells [10,11].
Despite recent advance in drug treatment and surgical
therapies, atherosclerosis remains to be a major cause of
death throughout the world. In coronary arteries, plaque
disruption is the majority of acute clinical manifestations
of atherosclerosis, leading to a subsequent cardiac event,
such as AMI and UA. Monocyte-derived macrophages. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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gression of atherosclerosis. Over-expression of MMP-9
and EMMPRIN in monocytes/macrophages results in
plaque progression and destabilization [6,12]. Plaque rup-
ture is thought to result from the degradation of extracel-
lular matrix components by macrophage-derived matrix
metalloproteinases (MMPs) [13]. Numerous reports
have shown that MMP-9 is one of the most important
MMPs contributing to plaque rupture, and its expres-
sion level is induced in serious coronary atherosclerosis
and AMI and UA [14]. In addition, MMP-9 induces
acute plaque disruption in Apoe−/−mice [15,16]. Previ-
ous reports demonstrated that MMP-13 is involved in
atherogenesis and decreasing plaque stability [17].
MMP-13 might be overexpressed in both human and
experimental atherosclerosis as well [18,19]. All these
data indicate that EMMPRIN-mediated MMPs induc-
tion is involved in the process of atherosclerotic lesion.
Base on these pieces of evidence, we hypothesized that
agents suppressing EMMPRIN and MMP-9 expression
would be potential therapeutic agents that ameliorate
the development of atherosclerosis. All these data indi-
cate that EMMPRIN-mediated MMP induction is in-
volved in the process of atherosclerotic lesion. Based
on these pieces of evidence, we hypothesized that
agents suppressing EMMPRIN and MMP-9 expression
would be potential therapeutic agents that ameliorate
the development of atherosclerosis.
During past few years, accumulating evidence has sug-
gested that curcumin has significant inhibitory effect on
MMPs in cancer, arthritis and ulcer [20]. Curcumin
(diferuloylmethane), a polyphenol derived from turmeric
and curcuma longa, is a pharmacologically safe and ef-
fective agent that plays an important role in anti-cancer
and anti-inflammatory processes. In atherosclerosis, cur-
cumin suppresses oxLDL (oxidized low-density lipopro-
tein) induced CD36 expression via inhibiting p38 MAPK
phosphorylation [21], and prevents the decrease of
thrombospondin-4 expression in oxLDL treated murine
macrophages [21]. Curcumin inhibits the adhesion of
monocytes to endothelial cells [22], and reduces the mi-
gration of HASMCs (human aortic smooth muscle
cells) by suppressing MMP-9 expression through down-
regulation of NF-κB -dependent pathways [23]. Further-
more, in vivo data showed that curcumin inhibits
atherosclerosis in ApoE(−/−) mice [22], and blocks the
development of atherosclerosis in ApoE/LDLR−/−mice
[24]. Although some studies have suggested the anti-
atherosclerosis activity of curcumin, the mechanism by
which curcumin regulates MMP-9, MMP-13 and EMM-
PRIN is currently unknown. The purpose of this study
was to uncover the mechanism by which curcumin reg-
ulates EMMPRIN, MMP-9 and MMP-13expression dur-
ing monocyte differentiation.Materials and methods
Cell culture
Human monocytic cell line THP-1 was obtained from
American Type Culture Collection (ATCC, Rockville, MD,
USA) and maintained at a density of 106/ml in RPMI 1640
medium containing 10% FBS, 10 mM HEPES (Sigma) and
1% pen/strep solution at 37°C, 5% CO2 incubator. Cells
were cultured in six-well plates for 48 h in the presence of
100 nM PMA, which allowed them to differentiate into ad-
herent macrophages [25]. Cells were pretreated with curcu-
min (0 to 50 μM, Sigma, USA) or 10 μM Compound C
(AMPK inhibitor), PD98059(MAPKK inhibitor), SB203580
(p38 MAPK inhibitor), and SP600125(JNK inhibitor) MAP
kinase inhibitors (Sigma, USA) for 1 hour, and then stimu-
lated with PMA for another 48 hours.
Cytotoxicity assay
PMA-induced macrophages were seeded in 96-well plates
at 6 × 103 cells/well. Twenty four hours later, cells were in-
cubated with curcumin (0 to 100 μM) for 48 h. Cells with-
out any treatment were used as a control. CCK8 assay
(WST-8, Dojindo, Kumamoto, Japan) was used to assess
the cytotoxicity of curcumin on PMA-induced macro-
phages, based on the manufacturer's recommendation.Protein isolation and Western blot analysis
Protein isolation and Western blot analysis of cell ly-
sates were performed as previously described [26].
Briefly, membranes were first probed with primary anti-
bodies for MMP-13(Proteintch,USA), EMMPRIN, PKCα,
PKCβ1 (Life Technologies, USA), MMP-9, phospho-ERK,
ERK, phospho-p38, p38, phospho-JNK, JNK, AMPK, p-
AMPKα (Cell Signaling Technology, Boston, MA) (1:1000
dilution in TBST), or β-actin (1:5000 dilution in TBST),
then incubated with anti-Rabbit or anti-mouse secondary
antibodies (Cell Signaling Technology, Boston, MA),
followed by incubation with antibody labeled with far-red
fluorescent Alexa Fluor 680 dye. All signals were detected
by the Odyssey imaging system (Li-cor, USA) and data
were normalized based on the β-actin level.RNA isolation, cDNA synthesis and real-time PCR
Total RNA was extracted from PMA-induced macro-
phages using Trizol reagent (Invitrogen) according to the
manufacturer's instructions. cDNA was synthesized using
the Reverse Transcription Kit (Takara) before Real-time
polymerase chain reactions were performed by SYBR Pre-
mix Ex Taq Kit (TaKaRa Code DRR041) according to the
instructions . The PCR reactions were performed in dupli-
cate and detected by the ABI-7500 Sequence Detection
System (USA). The primer sequences are listed in Table 1.
All results were normalized against the GAPDH level.
Table 1 Primers used in realtime-PCR to measure the mRNA expression of MMP-9, MMP-13 and EMMPRIN
Primer for realtime-PCR
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Cells in the logarithmic phase were seeded in 6-well
plate at the density of 3 × 105 cells per well. After incu-
bated in serum-free medium with or without curcumin
(6.25, 25 and 50 μM) for 1 hour, cells were incubated
with 100 μM PMA for another 48 h. culture superna-
tants were collected, 10 μl aliquots of the culture super-
natant were loaded onto a 10% polyacrylamide gel
containing 1 mg/ml gelatin. After electrophoresis, gels
were washed twice with 2.5% Triton X-100 (37°C,
15 min) and then gels were incubated at 37°C for 11 h
in developing buffer containing 10 mM Tris Base,
40 mM Tris–HCl, 200 mM NaCl, 10 mM CaCl2, 0.02%
Brij 35. Gels were subsequently stained with 0.5% (w/v)
Coomassie Blue R-250 for 2 h followed by destaining
with a solution containing 50% methanol, 10% glacial
acetic acid, 40% water. MMP-9-digested regions were
visualized as light bands against a dark background. An
image of each gel was detected by an Odyssey imaging
system (Li-cor, USA).
Statistical analysis
Data were presented as mean ± S.D and analyzed by one-
way ANOVA. P < 0.05 was considered statistically signifi-
cant. All experiments were performed at least three times.
Results
The cytotoxicity effect of curcumin on cells
To evaluate the cytotoxicity of curcumin on PMA-
induced macrophages, cells were treated with 5, 10, 25,
50, 75 and 100 μM curcumin for 48 h, and then cell viabil-
ity was detected by CCK-8 assay. As shown in Figure 1A,
low-dose curcumin (≤50 μM) did not significantly (<10%)
affect the cell viability. Therefore, cells were treated with
dose less than 50 μM for no more than 48 hours in subse-
quent experiments.
Curcumin reduces MMP-9, MMP13 expression and
MMP-9 activity
Elevated MMP-9 expression level was previously reported
during the monocyte differentiation to macrophages, while
MMP-13 expression level was unknown. To determine
whether curcumin has any effect on MMP-9 and MMP-
13 during the cell differentiation, THP-1 cells were pre-
treated with the indicated concentration of curcumin for1 h, followed by incubating with 100 nM PMA for 48 h.
Our results showed that curcumin significantly inhibited
the upregulation of MMP-9 and MMP-13 induced by
PMA, at both protein and mRNA levels, in a dose-
dependent manner (Figure 1B-D). Because MMP-9 is re-
ported to remarkably enhance elastin degradation in vitro
and induce plaque rupture in vivo [15,27], we examined
the effect of curcumin on MMP-9 enzymatic activity by
SDS-polyacrylamide gelatin zymography assay. As previ-
ously reported, after overnight in-gel digestion, the gelatin-
containing gel stained with coomassie blue showed an
unstained transparent band at approximate 92 KDa, which
was corresponding to the theoretical size of gelatin digested
by MMP-9 [28]. In THP-1-derived macrophages, curcumin
inhibited MMP-9 activity in a dose-dependent manner, as
evidenced by gelatin zymography assay (Figure 2A,B). All
the above data suggested that curcumin reduced MMP-
13, MMP-9 expression and MMP-9 activity in a dose-
dependent manner.
Curcumin reduces EMMPRIN expression in a
dose-dependent manner
EMMPRIN is the major and most characterized cell
surface regulator of MMP-9 and MMP-13 production
[11,12,18,19]. Since curcumin apparently down-regulates
MMP-9 and MMP-13 expression in PMA-induced macro-
phages, we next tested whether the inhibitory effect of cur-
cumin on MMP-9 and MMP-13 expression was due to the
inhibition of EMMPRIN expression in PMA-induced mac-
rophages. Indeed, our results showed that EMMPRIN ex-
pression was suppressed by curcumin in a dose-dependent
manner at both protein and mRNA level (Figure 1B-D),
suggesting that the down-regulation of EMMPRIN by cur-
cumin is, at least in part, responsible for the reduction of
MMP-9 expression in PMA-induced macrophages.
Curcumin inhibits chronic AMPK activation induced by PMA
We further tested whether AMPK activation was involved
in inhibiting MMP-9 and EMMPRIN expression by curcu-
min. Cells were pretreated with different doses of curcumin
for 1 hour and induced with PMA for another 48 hours,
then the phosphorylation of AMPKα and total AMPKα
was examined by Western blot. As shown in Figure 2C-D,
the total AMPK increased slightly in the PMA group and
curcumin can attenuates upregulation of total AMPK
Figure 1 Curcumin suppresses MMP-9, MMP13 and EMMPRIN expression in PMA induced macrophages. A. Effect of curcumin on cell
viability. PMA-induced macrophages were treated with indicated concentrations of curcumin (5–100 μM) for 48 h, and cell viability was assessed using the
CCK-8 assay. Cells incubated in a medium without curcumin were defined as a control and were considered 100% viable. B-D. Curcumin suppresses
EMMPRIN, MMP-9 and MMP13 expression in PMA-induced macrophages. The mRNA level and protein level were measured by Real-time PCR and
Western blot, respectively. *P < 0.05 vs PMA group, **P < 0.05 vs CTL group. CTL indicates that cells incubated in a medium without curcumin. 6.25 μM,
25 μM, 50 μM indicates that THP-1 cells were pretreated with indicated concentrations of curcumin before stimulating with 100 nM PMA for another
48 h. Cur: curcumin.
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in THP-1 cells. Importantly, curcumin remarkably abol-
ished AMPKα activation in a dose-dependent manner.
Curcumin suppresses MAPK and PKC pathways in
PMA -induced THP-1 cells
Previous studies from other groups and our group indicate
that PMA promotes the level of EMMPRIN and MMP-9
through activating MAPK signaling pathways [8,29,30].
PMA also is a strong inducer of protein kinase C, pkc sig-
nal paly a role during PMA induced cell differentiation and
adhension [31,32]. Thus, we wondered whether the reduced
EMMPRIN expression was through the MAPK or PKC
pathway. To test this hypothesis, THP-1 cells were first pre-
treated with curcumin for 1 hour before incubating with
PMA for another 48 hours. Western data showed that cur-
cumin significantly inhibited the phosphorylation of ERK1/
2, p38 MAPK, JNK and PKCα, PKCβ1 induced by PMA
(Figure 3A-B). To further explore which MAPK signaling
involved in the upregulation of MMP-9, MMP13 andEMMPRIN in PMA induces THP-1 cell. We next examine
the expression of them after treated with ERK1/2-specific
inhibitor (PD98059), p38-specific inhibitor (SB203580), and
JNK-specific inhibitor (SP600125).As shown in Figure 4,
ERK1/2 and JNK-specific inhibitor significantly downregu-
lated MMP-9 expression, and activation ,and p38-specific in-
hibitor showed weaker function. ERK1/2 and p38-specific
inhibitor inhibitor significantly decreased EMMPRIN expres-
sion, whereas JNK specific inhibitor showed no inhibitory
effect (Figure 4A,C). For MMP-13, ERK1/2, p38 and JNK-
specific inhibitor at high dose showed remarkable inhibitory
effect(Figure 4B,D). In conclusion, our result suggest that
MAPK signaling and PKC pathways are involved in the
regulation of EMMPRIN, MMP-9 and MMP-13 expression.
Curcumin suppresses MMP-9 and EMMPRIN expression
by inhibiting phosphorylation of AMPK through
MAPK pathways
To further elucidate whether AMPK has an effect on
MAPK pathway after cells exposed to curcumin, we first
Figure 2 Curcumin suppresses the activation of MMP-9 and chronic AMPK activation. A-B. Effect of curcumin on the activity of MMP-9
from cultured supernatant. THP-1 cells were pretreated with curcumin before stimulating with PMA (100 nM) for another 48 h. MMP-9 activities
were detected by gelatin zymography assay (A), and the corresponding densitometric measurement was shown in B. Cur: curcumin. C-D. Effect
of curcumin on total AMPK and phospho-AMPKα (Thr172). Differentiated THP-1 cells were treated with indicated agents and assayed by Western
blot using indicated antibodies (C), and the corresponding densitometric measurement was shown in D. *P < 0.05 vs PMA group, **P < 0.05 vs
CTL group.
Figure 3 Curcumin inhibits JNK, ERK, and p38 phosphorylation and PKC pathway. A. Differentiated THP-1 cells were treated with indicated
agents, and assayed by Western blot using indicated antibodies. Cells were pretreated with vehicle or curcumin at the indicated concentration
(5–50 μM) for 1 h, followed by PMA for 48 h. B. Protein quantification was carried out by densitometric analysis. Normalized proteins of JNK,
p-JNK, ERK, p-ERK, p38 and p-p38 were normalized based on the internal control β-actin. C. Expression of PKC-α and PKC-β1,cells were pretreated with
vehicle or curcumin at the indicated concentration (5–50 μM) for 1 h, followed by PMA for 48 h. D. Densitometry measurements of protein analysis.
The mean density values of PKC-αand PKC-β1 are expressed as ratios relative to that of β-actin. *P < 0.05 vs PMA group, **P < 0.05 vs CTL group.
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Figure 4 PMA induced EMMPRIN, MMP-9 and MMP13 expression by macrophages is blocked by a specific ERK, p38 and/or JNK inhibitors.
A-B. The addition of a specific ERK inhibitor (PD98059, 5 and 20 μM), p38 inhibitor (SB203580, 2.5 and 10 μM) completely blocks PMA-induced MMP-9
protein expression and activation, and p38-specific inhibitor showed weaker function. ERK1/2 and p38-specific inhibitor inhibitor significantly decreased
EMMPRIN expression, whereas JNK specific inhibitor showed no inhibitory effect. C-D. ERK1/2, p38 and JNK-specific inhibitor at high dose showed
remarkable inhibitory effect on MMP-13 expression. *P < 0.05 vs PMA group, #P >0.05 vs PMA group.
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9, MMP-13 and EMMPRIN expression. As shown in
Figure 5A-C, inhibition AMPK by compound C (AMPK in-
hibitor) dramatically suppressed MMP-9, MMP-13 and
EMMPRIN expression, indicating that AMPK chronic acti-
vation are important for PMA induced MMP-9, MMP-13
and EMMPRIN expression. Thus, inhibiting the activation
of AMPK by curcumin (Figure 2C) may also contribute
to attenuated MMP-9, MMP-13 and EMMPRIN expres-
sion. In addition, compound C also reduced the phos-
phorylation of p38, JNK, and ERK in PMA induced
THP-1 cells (Figure 4D-E), suggesting that the AMPK
inhibitor diminished the activation of p38, JNK, and
ERK pathways. Taken together, we concluded that cur-
cumin significantly inhibited phosphorylation AMPK
through MAPK pathways in dose-dependent manner,
which led to down-regulated EMMPRIN and MMP-9
expression in PMA-induced THP-1 cells.
Discussion
In this study, our data support a novel effect of curcu-
min on the expression level of EMMPRIN, MMP-9 and
MMP-13, suggesting that curcumin could be a potential
therapeutic agent for ameliorating the development of
atherosclerosis plaque. We found that curcumin inhibits
EMMPRIN MMP-9 and MMP-13, expression via PKC
and AMPK-dependent pathway in PMA induced THP-1
cells. Elevated expression and activity of MMP-13,
MMP-9 and EMMPRIN are correlated with advancedatherosclerotic lesions followed by plaque rupture and
myocardial infarction [8,19,33,34],which can be inhibited
by curcumin.
To elucidate the molecular mechanisms underlying
anti-atherolsclerosis activity of curcumin in PMA in-
duced THP-1 cells, we first measured the protein level
of phosphorylated AMPKα in THP-1 differentiated
macrophage. AMPK, the master regulator of energy me-
tabolism, emerges as a kinase that controls glycogen
utilization, lipid metabolism, fatty acid uptake and oxida-
tion, and protein synthesis [35,36]. AMPK is also neces-
sary for the invasive ability, the MMP-9 activity of
THP-1 cells [37,38], and PMA induced THP-1 cell adhe-
sion to endothelial cells [39]. PMA has been shown to
induce the activation of AMPKα, and the inactivation of
AMPKα resulted in down-regulation of MMP-9, MMP-
13 and EMMPRIN. As reported previously, Curcumin
was shown to inhibit the activation of AMPKα, although
other research demonstrated different result [40,41]. The
discrepancy may be due to different cell type and/or dif-
ferent inducing condition. However, no study has deter-
mined the role of curcumin in the long term activation of
AMPKα. In our study, we found that AMPK is activated
during 48 h PMA induced cell differentiation, and curcu-
min suppresses the chronic activation of AMPKα in a
dose-dependent manner. Consistent with our data, the
activation of AMPKs has been reported to induce cell
differentiation, including bone marrow-derived cells dif-
ferentiation into endothelial cells [42] and osteoblastic
Figure 6 Model for regulation of MMP-9, MMP-13 and EMMPRIN by curcumin. PMA induced EMMPRIN, MMP-9 and MMP13 expression by
macrophages through AMPK and PKC pathway.Curcumin attenuates expression of MMP-9, MMP-13 and EMMPRIN by inhibiting the activation of
AMPK and PKC pathway.
Figure 5 AMPK inhibitor mediated EMMPRIN, MMP-9 and MMP13 expression inhibition depends on the activation of MAPK pathway.
A-C. Compound C, AMPK inhibitor, significantly inhibits EMMPRIN, MMP-9 and MMP13 expression in PMA induced THP-1 cells. Cells were
pretreated with vehicle or Compound C (10 μM) for 1 h, followed by PMA for 48 h. The mRNA level of EMMPRIN, MMP-9 and MMP13 was
determined by qPCR (A), and protein level was determined by Western blot (B) and quantified by densitometric analysis (C). Comp C indicates
group treated with compound C; P + C indicates group treated with both PMA and compound C. D-E. Compound C inhibited the activation of
MAPK pathway. Differentiated THP-1 cells were treated with indicated agents, and assayed by Western blot using indicated antibodies (D) and
quantified by densitometric analysis (E). *P < 0.05 vs PMA group, **P < 0.05 vs CTL group.
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pound C (AMPK inhibitor) inhibits MMP-9, MMP-13
and EMMPRIN expression level in PMA induced THP-1
cell differentiation. PKC signal were actived during PMA
induced cell differentiation and adhesion [31,32]. Our
found showed PKC was actived by in PMA induced THP-
1 cells, curcumin can inhibit the activation of PKCα and
PKCβ1. Therefore, through inactivating AMPKs and PKC,
curcumin decreases the MMP-9, MMP-13 and EMM-
PRIN level which results in inhibiting monocyte/macro-
phage differentiation.
In addition, compound C also suppress the phosphor-
ylation of three major classes of MAP kinase signaling
(ERK, JNK, and p38), suggesting that curcumin may
suppress MMP-9, MMP-13 and EMMPRIN level by in-
activation of MAPK pathways. Previous data indicate
that EMMPRIN and MMPs can be regulated by different
factors, especially in MAPK pathways. For example, Lee
et al. reported that MMP-9 production was enhanced in
murine macrophages via activation of ERK and p38
MAPK [44,45]. Moreover, MMP-9, MMP13 and EMM-
PRIN level can be suppressed by ERK inhibitors or JNK
siRNA [3,46,47]. Consistent with our previous studies
[28,29], MAPK cascades (p38, ERK1/2, and JNK) are ac-
tivated to induce the expression of MMP-9 [48-50],
MMP13 [51,52] and EMPRIN [53,54].
As shown in this study, PMA induced the phos-
phorylation of ERK1/2, p38 and JNK. Curcumin in-
hibits MAPKs phosphorylation, which contributes to
the down-regulation of MMP-9, MMP-13 and EMMPRIN
expression. This was further supported by the finding
that the specific inhibitor of ERK1/2, p38 and JNK
showed different extent in PMA induced protein ex-
pression. Similarly, we found that compound C sup-
presses the phosphorylation of ERK1/2, p38 and JNK, and
the expression of MMP-9 and EMMPRIN. All these results
suggest that curcumin suppresses the activation of ERK1/2,
p38 and JNK by inhibiting p-AMPK and PKC.Conclusion
In summary, we showed that curcumin attenuates
MMP-9, MMP-13 and EMMPRIN expression through
the down-regulation of the AMPK and PKC pathway.
(Figure 6). Moreover, we identified AMPK as a novel
negative regulator of MMP-9 and EMMPRIN expression
in THP-1 cell during differentiation. We also indicate that
AMPK - MAPK and PKC pathways are involved in inhi-
biting MMP-9, MMP-13 and EMMPRIN expression. Be-
cause MMP-9 and MMP-13 plays an important role in the
rupture of atheromatous plaques, our findings shed novel
insight into the regulatory mechanism of MMP-9 and
MMP-13 expression, the function of AMPK, and a poten-
tial treatment of atherosclerosis by curcumin.Competing interests
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